RXi Pharmaceuticals Corporation, an RNA-targeted technologies company, today announced positive results from their second placebo-controlled Phase 1 study with RXI‑109, an sd-rxRNA compound that targets Connective Tissue Growth Factor (CTGF), and is being developed for the treatment of abnormal dermal scars such as hypertrophic scars and keloids in conjunction with scar revision surgery.
In this study, subjects received small skin incisions in their abdomen and were treated with 3 intradermal doses of RXI‑109 over a 2-week period. This dose escalating study consisted of 3 cohorts of 3 healthy volunteers each. Subjects received RXI‑109 on one side of the abdomen, and placebo on the other side.
Subjects were monitored for safety and local and systemic side effects over a total study period of 84 days.
Multiple dermal injections were well tolerated at all doses and treatment with RXI‑109 resulted in dose-dependent silencing of CTGF mRNA in the treated areas.
Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals said that, "We are very pleased with the outcome of this second Phase 1 study. These results show that multiple intradermal injections of RXI‑109 are well tolerated with minimal and mild side effects. He added that, "The work done in the last year has confirmed that our proprietary self-delivering RNAi technology (sd-rxRNA) reduces CTGF mRNA in humans in line with its mechanism of action. Indeed, results from this second study demonstrate that mRNA for CTGF in the incisions is reduced in a dose-dependent manner by RXI‑109 as compared to placebo. Our first Phase 1 study had already shown that a single dose of the drug lowered the actual protein content for CTGF also in a dose-dependent manner. With this exciting outcome, we are ready to embark on Phase 2 development in patients with hypertrophic scars and keloids."
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Could A Star Orbit A Planet? - Just For Fun
- Supertranslations And Eternal Ghosts: Black Holes No Closer To Being Understood
- Bel's Temple in Palmyra Is No More
- Blade Runner: The Science In The Fiction
- Highlights From ICNFP 2015
- If Happy Meal Law Passes, NYC Kids Will Frown
- Innate GMO Potato Deregulated By USDA
- "I should say that I am pissed off, and at the same time I feel ashamed as I do seem to care more..."
- "Could the Run 251244 Event 204117665 pp -> ZZ -> 2e2mu = 4L event be due to a Higgs mass state..."
- "There doesn't appear to be a particularly notable degree of collegiality here. Science isn't a..."
- "It is hard to admit it, but the suffering and death of civilians in Syria and elsewhere usually..."
- "We are living 21 century, everybody are thinking invention new technology. In this situation this..."
- Not All Expensive Drugs Are Equal
- Conundrum Confronts DCIS Breast Cancer Patients
- Germany Rightly Skewered for GMO Nonsense; Kudos for WSJ
- Expect Only Frowns if Silly Happy Meal Law Passes
- “Shock Therapy” – Not a Cuckoo’s Nest, a Valid Depression Rx
- Innate: Simplot genetically engineered potato gets USDA nod for deregulation
- Relativistic Heavy Ion Collider confirms tiny drops of early universe 'perfect' fluid
- Magnetic fields provide a new way to communicate wirelessly
- With tobacco, what you don't know can kill you sooner
- Isthminia panamensis: New species of ancient river dolphin discovered
- Smoking prevalence stays the same but people who want to quit are up